PDX (Patient Derived Xenograft) Mouse Model Database
Search the World’s 2nd Largest PDX Biobank
- 2000 PDX Mouse Models
- World’s Largest Biobank of Pretreated Models
- 900 Models with Full Treatment History
- 50 Oncology Indications Covered
- Hematology and Brain Metastasis Orthotopic Models
- Variant Rich: Naturally-Derived Resistance and Rare Mutations
LIDE’s translational network across 100 hospitals offers us daily access to fresh tumor samples. The most interesting tissues are immortalized in LIDE’s 2000 patient-derived (PDX) mouse models and 100+ proprietary, conditionally reprogrammed cell lines, giving our clients access to unique, patient-consented, highly characterized, low-passage tumors. Data from over 1800 of these models is now available directly for our clients in LIDE’s PMed Trial Database.
Already got an approval code? Access here.
Quality Data and Advance Search Functions
- Growth Curves | SOC
- DNA | RNASeq
- Gene Expression | Fusion | CNV | Mutation
- Patient Details | Treatment History
- Added soon: IHC | HE Pathology | HLA Types
- Updated weekly
Reliable science requires clarity of data
LIDE’s in-house bioanalytics team has standardized data across all our sources, applying quality controls where needed, and reprocessing data if necessary. Search with confidence that the data is accurate and dependable for your study needs.
Summary of Available Models
| Cancer | No. |
|---|---|
| Acute lymphoblastic leukemia | 12 |
| Acute myelocytic leukemia | 16 |
| Adenoid cystic carcinoma (ACC) | 5 |
| Bladder cancer | 5 |
| Brain cancer | 69 |
| Breast cancer | 45 |
| Cervical cancer | 55 |
| Cholangiocarcinoma | 82 |
| Chordoma | 2 |
| Chronic Lymphocytic Leukemia | 2 |
| Colon cancer | 116 |
| Duodenal carcinoma | 15 |
| Endometrial cancer | 17 |
| Esophageal cancer | 42 |
| Extramedullary tumor | 1 |
| Fallopian tube carcinoma | 2 |
| Gallbladder carcinoma | 36 |
| Gastric cancer | 202 |
| Gastrointestinal stromal tumor | 6 |
| Hepatoblastoma | 42 |
| Hepatocellular | 103 |
| Head and neck cancer | 7 |
| Lung cancer | 161 |
| Lymphoma | 16 |
| Malignant mesothelioma | 2 |
| Mediastinal endoblastoid sinus tumor | 1 |
| Melanoma | 4 |
| Mucinous carcinoma | 5 |
| Multiple Myeloma | 3 |
| Neuroendocrine tumor | 6 |
| Osteosarcoma | 58 |
| Ovarian cancer | 203 |
| Paget’s Disease | 1 |
| Pancreatic cancer | 305 |
| Penile cancer | 2 |
| Periampullary carcinoma | 2 |
| Prostate cancer | 7 |
| Rectal Cancer | 81 |
| Renal carcinoma | 9 |
| Sarcoma | 38 |
| Spleen cancer | 1 |
| Urethral carcinoma | 4 |
*last updated 3Q2023
Best in Class Models for Quality Results
- Follows Highest International Standards
- Patient Consented, IRB Approved
- Efficacy Studies at P3
Reliable science requires quality inputs.
Our biobank was built from the beginning according to standards set by a PDX Consortium led by LIDE in collaboration with EMD Serono, Lilly and Merck. Our seed bank is stored at P0-P2 with a separate application bank at P3-P10 to support client studies. Most preclinical tests are done using P3 – P5 when possible. All models are sequenced and searchable according to target mutations and/or phenotypes. Patient history, IHC and SOC studies included where available..
12 Years of Preclinical Research Experience
- 2500 Studies across 200 Clients
- Preclinical Pharmacology is our Core Expertise
Our offering includes traditional, gold standard methods as well as LIDE-unique techniques that ensure we’re delivering quality science while being efficient with our client’s time and dollars. Each study is available as a stand-alone service or as part of an end-to-end preclinical, IND-enabling program.
With over 12 years of experience specifically in the preclinical oncology space, and experienced PhD scientists, lab technicians and bioinformaticians, you can trust LIDE with your study needs.